# US 6,727,104 B2 · Microcolumn chromatographic immunoassays

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,104 B2
- Document ID: US6727104B2
- Status: Granted
- Kind: B2
- Application number: 09/863,631
- Filed: 2001-05-23
- Published: 2002-10-17
- Granted: 2004-04-27
- Earliest claimed: 2001-02-05
- Assignees: Board of Regents of the University of Nebraska
- Inventors: David S. Hage; William A. Clarke
- Web page: https://patentgrep.com/patent/US6727104B2

## CPC

- G01N 33/54393: {Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding}
- G01N 33/54313: {the carrier being characterised by its particulate form}
- G01N 33/54366: {Apparatus specially adapted for solid-phase testing}
- G01N 2030/527: {sorbent material in form of a membrane}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention is generally directed toward an analytical method to determine the concentration of an analyte or free analyte fraction in a sample. More particularly, the method encompasses applying a sample containing an analyte to an immunoaffinity column capable of selectively extracting the analyte in the millisecond time domain. The concentration of the analyte is then determined by chromatographic immunoassay.

## Claims

### Claim 1

A method to determine the concentration of an analyte in a sample, the method comprising:
(a) applying the sample to an immunoaffinity column having an active layer which selectively binds analyte present in the sample, the sample being applied at a rate and under a pressure to cause the sample to pass through the active layer in less than a second, wherein the column separates the analyte from the sample in the millisecond time domain; and
(b) determining the concentration of analyte present in the sample by chromatographic immunoassay.

### Claim 2 (depends on 1)

The method of claim 1 wherein the active layer comprises support particles derivatized with a binding agent.

### Claim 3 (depends on 2)

The method of claim 2 wherein the active layer is from about 10 microns to about 1.1 millimeters in length.

### Claim 4 (depends on 2)

The method of claim 2 wherein the active layer is not less than 60 microns in length.

### Claim 5 (depends on 2)

The method of claim 2 wherein the binding agent is selected from the group of agents consisting of antibodies, aptamers, antibody fragments, synthetic molecular imprints, antibody related molecules and recombinant proteins.

### Claim 6 (depends on 5)

The method of claim 5 wherein the binding agent is comprises antibodies.

### Claim 7 (depends on 6)

The method of claim 6 wherein the binding agent has a high binding affinity for the analyte.

### Claim 8 (depends on 7)

The method of claim 7 wherein the binding agent has a binding affinity for the analyte from about 102 to about 106 M−1.

### Claim 9 (depends on 7)

The method of claim 7 wherein the binding agent has a binding affinity for the analyte greater than about 106 M−1.

### Claim 10 (depends on 7)

The method of claim 7 wherein the analyte is separated from the sample from about 1 to about 500 milliseconds after injection of the sample into the column.

### Claim 11 (depends on 7)

The method of claim 7 wherein the analyte is separated from the sample from about 1 to about 100 milliseconds after injection of the sample into the column.

### Claim 12 (depends on 1)

The method of claim 1 wherein the chromatographic immunoassay is a competitive binding immunoassay.

### Claim 13 (depends on 12)

The method of claim 12 wherein the competitive binding immunoassay is selected from the group of immunoassays consisting of simultaneous injection immunoassay, sequential addition immunoassay, and displacement binding immunoassay.

### Claim 14 (depends on 13)

The method of claim 13 wherein the competitive binding immunoassay is a displacement binding immunoassay.

### Claim 15 (depends on 1)

The method of claim 1 wherein the chromatographic immunoassay is a one-site immunometric assay.

### Claim 16

A method to determine the concentration of a free analyte fraction in a sample, the sample comprising a biological fluid having a bound analyte fraction and a free analyte fraction, the method comprising:
(a) applying the sample to an immunoaffinity column having an active layer that selectively binds free analyte relative to bound analyte, the sample being applied at a rate and under a pressure to cause the sample to pass through the active layer in less than a second, wherein the column separates the free analyte fraction from the sample in the millisecond time domain; and
(b) determining the concentration of free analyte present in the sample by chromatographic immunoassay.

### Claim 17 (depends on 16)

The method of claim 16 wherein the active layer comprises support particles derivatized with a binding agent.

### Claim 18 (depends on 17)

The method of claim 17 wherein the active layer is from about 10 microns to about 1.1 millimeters in length.

### Claim 19 (depends on 17)

The method of claim 17 wherein the active layer is not less than 60 microns in length.

### Claim 20 (depends on 17)

The method of claim 17 wherein the binding agent is selected from the group of agents consisting of antibodies, aptamers, antibody fragments, synthetic molecular imprints, antibody related molecules and recombinant proteins.

### Claim 21 (depends on 20)

The method of claim 20 wherein the binding agent is antibodies.

### Claim 22 (depends on 21)

The method of claim 21 wherein the binding agent has a high binding affinity for the free analyte fraction.

### Claim 23 (depends on 22)

The method of claim 22 wherein the binding agent has a binding affinity for the free analyte fraction from about 102 to about 106 M−1.

### Claim 24 (depends on 22)

The method of claim 22 wherein the binding agent has a binding affinity for the free analyte fraction greater than about 106 M−1.

### Claim 25 (depends on 22)

The method of claim 22 wherein the free analyte fraction is separated from the sample from about 1 to about 500 milliseconds after injection of the sample into the column.

### Claim 26 (depends on 22)

The method of claim 22 wherein the free analyte fraction is separated from the sample from about 1 to about 100 milliseconds after injection of the sample into the column.

### Claim 27 (depends on 16)

The method of claim 16 wherein the chromatographic immunoassay is a competitive binding immunoassay.

### Claim 28 (depends on 27)

The method of claim 27 wherein the competitive binding immunoassay is selected from the group of immunoassays consisting of simultaneous injection immunoassay, sequential addition immunoassay, and displacement binding immunoassay.

### Claim 29 (depends on 28)

The method of claim 28 wherein the competitive binding immunoassay is a displacement binding immunoassay.

### Claim 30 (depends on 16)

The method of claim 16 wherein the chromatographic immunoassay is a one-site immunometric assay.

### Claim 31 (depends on 10)

The method of claim 10 wherein the active layer is introduced by a plurality of injections.

### Claim 32 (depends on 31)

The method of claim 31 wherein the active layer is introduced by about 10 to about 100 injections.

### Claim 33 (depends on 31)

The method of claim 31 wherein the active layer is introduced by about 30 to about 40 injections when the active layer is from about 100 to about 500 microns in length.

### Claim 34 (depends on 31)

The method of claim 31 wherein the active layer is introduced by about 60 to about 80 injections when the active layer is from about 60 to about 100 microns in length.

### Claim 35 (depends on 31)

The method of claim 31 wherein the support particles comprising the active layer are injected onto the column at a density of from about 0.1 to about 20 milligrams of support particle per milliliter of packing solvent.

### Claim 36 (depends on 31)

The method of claim 31 wherein the biological fluid is selected from the group consisting of blood, plasma, urine, cerebrospinal fluid, a tissue sample, and intracellular fluid.

### Claim 37 (depends on 36)

The method of claim 36 wherein the binding capacity of the active layer comprises a ratio of the number of active binding sites to amount of analyte present in the sample between about 1:1 to about 10:1.

### Claim 38 (depends on 37)

The method of claim 37 wherein the sample is injected onto the column at a flow rate of about 0.01 to about 9.0 milliliters per minute.

### Claim 39 (depends on 37)

The method of claim 37 wherein the sample is injected onto the column under a pressure of about 100 to about 1500 psi.
